Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) will deliver a poster presentation titled “Inhibition of Hepatocellular Carcinoma Growth and Liver Fibrosis by Nanomolar Cannabinoids Concentrations” at the CannX Medical Cannabis Conference in Tel Aviv which takes place March 14 – 15, 2022. The abstract will additionally be published in the peer-reviewed scientific journal Medical Cannabis and Cannabinoids.
Cannabinoids bind to CB1 and CB2 receptors regulating the function of multiple organs and tissues of the body. Interestingly, cannabinoids also bind to Can-Fite’s platform technology’s primary target, the Gi protein associated A3 adenosine receptor which is up-regulated in inflammatory and tumor cells.
